Overview

A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how the pharmacokinetics of apremilast may be affected by a single intravenous dose of rifampin and multiple oral doses of rifampin.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Celgene Corporation
Treatments:
Apremilast
Rifampin
Thalidomide